Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose Mayordomo

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Critical Reviews in Oncology/Hematology|September 20, 2005
Epoetin beta therapy in patients with solid tumoursPaolo Pronzato, Jacek Jassem, Jose Mayordomo
Oncology (Williston Park, N.Y.)|December 18, 2016
Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing StrategiesLinda Overholser, Elena Shagisultanova, Rachel A Rabinovitch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast CancerElena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, et al.
Cancer Chemotherapy and Pharmacology|September 29, 2007
Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC)Fernando Rivera, M Eugenia Vega-Villegas, Marta López-Brea, et al.
The Lancet. Oncology|November 18, 2022
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion studyFunda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, et al.
NPJ Breast Cancer|May 20, 2023
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancerAnthony D Elias, Nicole S Spoelstra, Alyse W Staley, et al.
Ebiomedicine|August 21, 2016
Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-AnalysisLi-Shiun Chen, Timothy Baker, Rayjean J Hung, et al.
Journal of the National Cancer Institute|April 16, 2015
CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysisLi-Shiun Chen, Rayjean J Hung, Timothy Baker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2019
Lung Cancer Risk in Never-Smokers of European Descent is Associated With Genetic Variation in the 5<sub>p</sub>15.33 TERT-CLPTM1Ll RegionRayjean J Hung, Margaret R Spitz, Richard S Houlston, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Critical Reviews in Oncology/Hematology|September 20, 2005
Epoetin beta therapy in patients with solid tumoursPaolo Pronzato, Jacek Jassem, Jose Mayordomo
Oncology (Williston Park, N.Y.)|December 18, 2016
Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing StrategiesLinda Overholser, Elena Shagisultanova, Rachel A Rabinovitch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast CancerElena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, et al.
Cancer Chemotherapy and Pharmacology|September 29, 2007
Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC)Fernando Rivera, M Eugenia Vega-Villegas, Marta López-Brea, et al.
The Lancet. Oncology|November 18, 2022
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion studyFunda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, et al.
NPJ Breast Cancer|May 20, 2023
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancerAnthony D Elias, Nicole S Spoelstra, Alyse W Staley, et al.
Ebiomedicine|August 21, 2016
Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-AnalysisLi-Shiun Chen, Timothy Baker, Rayjean J Hung, et al.
Journal of the National Cancer Institute|April 16, 2015
CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysisLi-Shiun Chen, Rayjean J Hung, Timothy Baker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2019
Lung Cancer Risk in Never-Smokers of European Descent is Associated With Genetic Variation in the 5<sub>p</sub>15.33 TERT-CLPTM1Ll RegionRayjean J Hung, Margaret R Spitz, Richard S Houlston, et al.
Pageof 1